WHO WE ARE
Improving the lives of patients and their families, by developing treatments for neurodegenerative and neurodevelopmental disorders, lies at the heart of Prilenia’s mission.
We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.
Our lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently in Phase 2 clinical development for the treatment of patients with Parkinson’s Disease suffering from Levodopa Induced Dyskinesia (PD-LID). We are planning to initiate a phase 3 trial in Huntington Disease in the near future.
Prilenia is based in Herzliya, Israel and in Boston, MA.